FindTrial
Sign In

Phase 2 Study of SK-1011 - Subfoveal choroidal neovascularization secondary to age-related macular degeneration -

Phase 2 Study of SK-1011 - Subfoveal choroidal neovascularization secondary to age-related macular degeneration -

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221648
Enrollment
Unknown
Registered
2011-11-11
Start date
2011-11-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfoveal choroidal neovascularization secondary to age-related macular degeneration

Interventions

investigational material(s) Generic name etc : SK-1011 INN of investigational material : Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational materi

Sponsors

SANWA KAGAKU KENKYUSHO CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye 2) Patients who have a BCVA ETDRS score between 73 and 24 letters in the study eye inclusive (approximately 0.5 to 0.06) 3) Patients who are capable of giving written informed consent

Exclusion criteria

Exclusion criteria: 1) Use of systemic anti-VEGF medication 2) Prior treatment in the study eye with anti-VEGFs, verteporfin, steroids, or laser photocoagulation within certain periods of time 3) Presence of retinal angiomatous proliferation (RAP) in the study eye 4) Medical conditions such as cancer, serious liver, renal cardiac disease

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026